BladderAI Project Successfully Completed: Advancing Early Bladder Cancer Detection

We are pleased to announce the successful finalization of the BladderAI project, a collaboration between NordicDx and UroScan, co-funded by the EU DESIRE initiative. This innovative project aimed to develop a groundbreaking, non-invasive method for the early detection of bladder cancer using spectrophotometric analysis of urine samples and advanced AI technology.

Throughout the project, we achieved remarkable outcomes:

• High Diagnostic Accuracy: The BladderAI algorithm demonstrated an accuracy rate of over 85 % in detecting bladder cancer biomarkers, providing a promising alternative to invasive diagnostic methods like cystoscopy.
• Improved Patient Experience: The new diagnostic approach significantly reduces the need for painful and costly procedures, offering a simple, non-invasive urine test that can be widely implemented in both hospital and non-hospital settings.
• Enhanced Accessibility and Cost Efficiency: By automating the analysis process, BladderAI offers a cost-effective solution that can be performed without the need for specialized medical personnel, making it accessible to more healthcare facilities.

We are excited about the potential impact of these findings on bladder cancer diagnostics and patient care. The completion of the BladderAI project represents a major step forward in meeting the market’s need for rapid, accurate, and non-invasive cancer screening solutions.

We extend our heartfelt thanks to our partners and the EU DESIRE initiative for their support throughout this endeavor. As we move forward, we are exploring ways to implement and expand the use of this innovative technology in clinical settings across Europe and beyond.

For more information or collaboration opportunities, please contact NordicDx or UroScan.